Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial

Table 5

Immune status of CRC patients before treatment began and after 6 cycles of adjuvant/palliative chemotherapy (FOLFOX4) without Uncaria tomentosa supply (C group) or receiving 300 mg/day of Uncaria tomentosa (UT group).

Parameters	Group	Chemotherapy cycles
		0	6
CD4^+ T Cells	UT	958.36 (414.6)	720.28 (271.72)
Cells/μL	C	828.45 (431.25)	848.38 (430.56)
CD8^+ T cells	UT	494.0 (231.28)	390.64 (223.62)
Cells/μL	C	490.29 (271.14)	394.27 (149.96)
CD4^+ T/CD8^+ T Ratio	UT	2.17 (0.76)	2.21 (0.78)
	C	1.96 (1.03)	2.30 (1.08)
IL6	UT	4.07^# (6.54)	5.1^# (6.12)
ng/mL	C	12.97 (13.28)	16.66 (18.2)

Data expressed as mean (SD); UT group: patients treated with FOLFOX4 + Uncaria tomentosa 300 mg/daily (𝑛=20); C group: CRC patients received FOLFOX4 (𝑛=23). ^#𝑃<0.05 between groups.